Histamine-4 Receptor: Emerging Target for the Treatment of Neurological Diseases.

Anaclet C, Parmentier R, Ouk K et al (2009) Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J Neurosci 29:14423–14438. https://doi.org/10.1523/JNEUROSCI.2604-09.2009

doi: 10.1523/JNEUROSCI.2604-09.2009 pubmed: 19923277 pmcid: 2802289

Anichtchik OV, Rinne JO, Kalimo H, Panula P (2000) An altered histaminergic innervation of the substantia nigra in Parkinson’s disease. Exp Neurol 163:20–30

doi: 10.1006/exnr.2000.7362

Apolloni S, Fabbrizio P, Amadio S et al (2017) Histamine regulates the inflammatory profile of SOD1-G93A microglia and the histaminergic system is dysregulated in amyotrophic lateral sclerosis. Front Immunol 8:1689. https://doi.org/10.3389/fimmu.2017.01689

doi: 10.3389/fimmu.2017.01689 pubmed: 29250069 pmcid: 5714870

Apolloni S, Amadio S, Fabbrizio P et al (2019) Histaminergic transmission slows progression of amyotrophic lateral sclerosis. J Cachexia Sarcopenia Muscle 10:872–893. https://doi.org/10.1002/jcsm.12422

doi: 10.1002/jcsm.12422 pubmed: 31020811 pmcid: 6711424

Aronica E, Baas F, Iyer A et al (2015) Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex. Neurobiol Dis 74:359–376. https://doi.org/10.1016/j.nbd.2014.12.002

doi: 10.1016/j.nbd.2014.12.002 pubmed: 25500340

Arrang JM, Garbarg M, Schwartz JC (1983) Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302:832–837

doi: 10.1038/302832a0

Arrang JM, Garbarg M, Schwartz JC (1985a) Autoregulation of histamine release in brain by presynaptic H3-receptors. Neuroscience 15:553–562. https://doi.org/10.1016/0306-4522(85)90233-7

doi: 10.1016/0306-4522(85)90233-7 pubmed: 4022339

Arrang JM, Schwartz JC, Schunack W (1985b) Stereoselectivity of the histamine H3-presynaptic autoreceptor. Eur J Pharmacol 117:109–114. https://doi.org/10.1016/0014-2999(85)90478-9

doi: 10.1016/0014-2999(85)90478-9 pubmed: 2417862

Arrang J-M, Devaux B, Chodkiewicz J-P, Schwartz J-C (1988a) H3-receptors control histamine release in human brain. J Neurochem 51:105–108. https://doi.org/10.1111/j.1471-4159.1988.tb04841.x

doi: 10.1111/j.1471-4159.1988.tb04841.x pubmed: 2454293

Arrang JM, Defontaine N, Schwartz JC (1988b) Phencyclidine blocks histamine H3-receptors in rat brain. Eur J Pharmacol 157:31–35. https://doi.org/10.1016/0014-2999(88)90467-0

doi: 10.1016/0014-2999(88)90467-0 pubmed: 2853072

Athauda D, Maclagan K, Skene SS et al (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664–1675. https://doi.org/10.1016/S0140-6736(17)31585-4

doi: 10.1016/S0140-6736(17)31585-4 pubmed: 28781108 pmcid: 5831666

Bassetti CLA, Adamantidis A, Burdakov D et al (2019) Narcolepsy – clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. https://doi.org/10.1038/s41582-019-0226-9

Beermann S, Seifert R, Neumann D (2012) Commercially available antibodies against human and murine histamine H(4)-receptor lack specificity. Naunyn Schmiedebergs Arch Pharmacol 385:125–135. https://doi.org/10.1007/s00210-011-0700-4

doi: 10.1007/s00210-011-0700-4 pubmed: 22071576

Betarbet R, Sherer TB, MacKenzie G et al (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–1306. https://doi.org/10.1038/81834

doi: 10.1038/81834 pubmed: 11100151

Bian Z, Gong Y, Huang T et al (2020) Deciphering human macrophage development at single-cell resolution. Nature 582:571–576. https://doi.org/10.1038/s41586-020-2316-7

doi: 10.1038/s41586-020-2316-7 pubmed: 32499656

Boillée S, Yamanaka K, Lobsiger CS et al (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312:1389–1392. https://doi.org/10.1126/science.1123511

doi: 10.1126/science.1123511 pubmed: 16741123

Braak H, Del Tredici K, Rub U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211

doi: 10.1016/S0197-4580(02)00065-9

Brabant C, Charlier Y, Navacerrada MES et al (2016) Action of Pitolisant on the stimulant and rewarding effects of cocaine in mice. Eur J Pharmacol 791:552–559. https://doi.org/10.1016/j.ejphar.2016.08.027

doi: 10.1016/j.ejphar.2016.08.027 pubmed: 27568835

Chiot A, Zaïdi S, Iltis C et al (2020) Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival. Nat Neurosci 23:1339–1351. https://doi.org/10.1038/s41593-020-00718-z

doi: 10.1038/s41593-020-00718-z pubmed: 33077946

Cicchetti F, Drouin-Ouellet J, Gross RE (2009) Environmental toxins and Parkinson’s disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci 30:475–483. https://doi.org/10.1016/j.tips.2009.06.005

doi: 10.1016/j.tips.2009.06.005 pubmed: 19729209

Dale HH, Laidlaw PP (1910) The physiological action of β-iminazolylethylamine. J Physiol 41:318–344. https://doi.org/10.1113/jphysiol.1910.sp001406

doi: 10.1113/jphysiol.1910.sp001406 pubmed: 16993030 pmcid: 1512903

Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 122(Pt 8):1437–1448

doi: 10.1093/brain/122.8.1437

Dauvilliers Y, Bassetti C, Lammers GJ et al (2013) Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol 12:1068–1075. https://doi.org/10.1016/S1474-4422(13)70225-4S1474-4422(13)70225-4

doi: 10.1016/S1474-4422(13)70225-4S1474-4422(13)70225-4 pubmed: 24107292

Deczkowska A, Keren-Shaul H, Weiner A et al (2018) Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell 173:1073–1081

doi: 10.1016/j.cell.2018.05.003

Desmadryl G, Gaboyard-Niay S, Brugeaud A et al (2012) Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability. Br J Pharmacol 167:905–916. https://doi.org/10.1111/j.1476-5381.2012.02049.x

doi: 10.1111/j.1476-5381.2012.02049.x pubmed: 22624822 pmcid: 3575788

Dettori I, Gaviano L, Melani A et al (2018) A selective histamine H4 receptor antagonist, JNJ7777120, is protective in a rat model of transient cerebral ischemia. Front Pharmacol 9. https://doi.org/10.3389/fphar.2018.01231

Dong H, Zhang W, Zeng X et al (2014) Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia. Mol Neurobiol 49:1487–1500. https://doi.org/10.1007/s12035-014-8697-6

doi: 10.1007/s12035-014-8697-6 pubmed: 24752587

Eglitis MA, Mezey É (1997) Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci U S A 94:4080–4085. https://doi.org/10.1073/pnas.94.8.4080

doi: 10.1073/pnas.94.8.4080 pubmed: 9108108 pmcid: 20571

Fang Q, Xicoy H, Shen J et al (2020) Histamine-4 receptor antagonist ameliorates Parkinson-like pathology in the striatum. Brain Behav Immun. https://doi.org/10.1016/j.bbi.2020.11.036

Ferreira R, Santos T, Gonçalves J et al (2012) Histamine modulates microglia function. J Neuroinflammation 9:90. https://doi.org/10.1186/1742-2094-9-90

doi: 10.1186/1742-2094-9-90 pubmed: 22569158 pmcid: 3583187

Frick L, Rapanelli M, Abbasi E et al (2016) Histamine regulation of microglia: gene-environment interaction in the regulation of central nervous system inflammation. Brain Behav Immun 57:326–337. https://doi.org/10.1016/j.bbi.2016.07.002

doi: 10.1016/j.bbi.2016.07.002 pubmed: 27381299 pmcid: 5012904

Galeotti N, Sanna MD, Ghelardini C (2013) Pleiotropic effect of histamine H4 receptor modulation in the central nervous system. Neuropharmacology 71:141–147. https://doi.org/10.1016/j.neuropharm.2013.03.026S0028-3908(13)00122-6

doi: 10.1016/j.neuropharm.2013.03.026S0028-3908(13)00122-6 pubmed: 23583928

Gondard E, Anaclet C, Akaoka H et al (2013) Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice. Neuropsychopharmacology 38:1015–1031. https://doi.org/10.1038/npp.2012.266npp2012266

doi: 10.1038/npp.2012.266npp2012266 pubmed: 23303066 pmcid: 3629391

Guo RX, Anaclet C, Roberts JC et al (2009) Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox−/− mice. Br J Pharmacol 157:104–117. https://doi.org/10.1111/j.1476-5381.2009.00205.x

doi: 10.1111/j.1476-5381.2009.00205.x pubmed: 19413575 pmcid: 2697793

Haas HL, Sergeeva OA, Selbach O (2008) Histamine in the nervous system. Physiol Rev 88:1183–1241

doi: 10.1152/physrev.00043.2007

Hardiman O, Al-Chalabi A, Chio A et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3

Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334:345–348

doi: 10.1038/334345a0

Hsieh GC, Chandran P, Salyers AK et al (2010) H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats. Pharmacol Biochem Behav 95:41–50. https://doi.org/10.1016/j.pbb.2009.12.004

doi: 10.1016/j.pbb.2009.12.004 pubmed: 20004681

Huyts B, Brabant C, Tirelli E (2019) Pitolisant and intravenous cocaine self-administration in mice. Eur J Pharmacol 851:63–68. https://doi.org/10.1016/j.ejphar.2019.02.019

doi: 10.1016/j.ejphar.2019.02.019 pubmed: 30771351

Karlstedt K, Jin C, Panula P (2013) Expression of histamine receptor genes Hrh3 and Hrh4 in rat brain endothelial cells. Br J Pharmacol 170:58–66. https://doi.org/10.1111/bph.12173

doi: 10.1111/bph.12173 pubmed: 23488566 pmcid: 3764849

Kollb-Sielecka M, Demolis P, Emmerich J et al (2017) The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use. Sleep Med 33:125–129. https://doi.org/10.1016/j.sleep.2017.01.002

doi: 10.1016/j.sleep.2017.01.002 pubmed: 28449891

Leurs R, Vischer HF, Wijtmans M, De Esch IJP (2011) En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. Trends Pharmacol Sci 32:250–257

doi: 10.1016/j.tips.2011.02.004

Lin JS, Dauvilliers Y, Arnulf I et al (2008) An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin−/− mice and patients. Neurobiol Dis 30:74–83. https://doi.org/10.1016/j.nbd.2007.12.003

doi: 10.1016/j.nbd.2007.12.003 pubmed: 18295497

Liu C, Ma X, Jiang X et al (2001) Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol 59:420–426

doi: 10.1124/mol.59.3.420

Lozovaya N, Eftekhari S, Cloarec R et al (2018) GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease. Nat Commun:9. https://doi.org/10.1038/s41467-018-03802-y

Masuda T, Sankowski R, Staszewski O et al (2019) Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566:388–392. https://doi.org/10.1038/s41586-019-0924-x

doi: 10.1038/s41586-019-0924-x pubmed: 30760929

Mehta P, Miszta P, Rzodkiewicz P et al (2020) Enigmatic histamine receptor h4 for potential treatment of multiple inflammatory, autoimmune, and related diseases. Life 10:50

doi: 10.3390/life10040050

Mittal S, Bjørnevik K, Im DS et al (2017) β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease. Science 357:891–898. https://doi.org/10.1126/science.aaf3934

doi: 10.1126/science.aaf3934 pubmed: 28860381 pmcid: 5761666

Morse KL, Behan J, Laz TM et al (2001) Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther 296:1058–1066

pubmed: 11181941

Nakamura T, Itadani H, Hidaka Y et al (2000) Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun 279:615–620. https://doi.org/10.1006/bbrc.2000.4008S0006-291X(00)94008-7

doi: 10.1006/bbrc.2000.4008S0006-291X(00)94008-7 pubmed: 11118334

Nguyen T, Shapiro DA, George SR et al (2001) Discovery of a novel member of the histamine receptor family. Mol Pharmacol 59:427–433. https://doi.org/10.1124/mol.59.3.427

doi: 10.1124/mol.59.3.427 pubmed: 11179435

Nishino S, Arrigoni J, Valtier D et al (1991) Dopamine D2 mechanisms in canine narcolepsy. J Neurosci 11:2666–2671. https://doi.org/10.1523/jneurosci.11-09-02666.1991

doi: 10.1523/jneurosci.11-09-02666.1991 pubmed: 1831837 pmcid: 6575243

Obara I, Telezhkin V, Alrashdi I, Chazot PL (2020) Histamine, histamine receptors, and neuropathic pain relief. Br J Pharmacol 177:580–599

doi: 10.1111/bph.14696

Oda T, Morikawa N, Saito Y et al (2000) Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 275:36781–36786. https://doi.org/10.1074/jbc.M006480200M006480200

doi: 10.1074/jbc.M006480200M006480200 pubmed: 10973974

Panula P, Nuutinen S (2013) The histaminergic network in the brain: basic organization and role in disease. Nat Rev Neurosci 14:472–487. https://doi.org/10.1038/nrn3526

doi: 10.1038/nrn3526 pubmed: 23783198

Panula P, Yang HYT, Costa E (1984) Histamine-containing neurons in the rat hypothalamus. Proc Natl Acad Sci 81:2572–2576. https://doi.org/10.1073/pnas.81.8.2572

doi: 10.1073/pnas.81.8.2572 pubmed: 6371818 pmcid: 345105

Panula P, Chazot PL, Cowart M et al (2015) International union of basic and clinical pharmacology. XCVIII. Histamine receptors. Pharmacol Rev 67:601–655. https://doi.org/10.1124/pr.114.010249

doi: 10.1124/pr.114.010249 pubmed: 26084539 pmcid: 4485016

Passani MB, Blandina P (2011) Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci 32:242–249. https://doi.org/10.1016/j.tips.2011.01.003

doi: 10.1016/j.tips.2011.01.003 pubmed: 21324537

Petremann M, Gueguen C, Delgado Betancourt V et al (2020) Effect of the novel histamine H4 receptor antagonist SENS-111 on spontaneous nystagmus in a rat model of acute unilateral vestibular loss. Br J Pharmacol 177:623–633. https://doi.org/10.1111/bph.14803

doi: 10.1111/bph.14803 pubmed: 31347148

Peyron C, Faraco J, Rogers W et al (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991–997. https://doi.org/10.1038/79690

doi: 10.1038/79690 pubmed: 10973318

Profaci CP, Munji RN, Pulido RS, Daneman R (2020) The blood–brain barrier in health and disease: important unanswered questions. J Exp Med 217

Qamhawi Z, Towey D, Shah B et al (2015) Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease. Brain 138:2964–2973. https://doi.org/10.1093/brain/awv215

doi: 10.1093/brain/awv215 pubmed: 26209314

Rinne JO, Anichtchik OV, Eriksson KS et al (2002) Increased brain histamine levels in Parkinson’s disease but not in multiple system atrophy. J Neurochem 81:954–960

doi: 10.1046/j.1471-4159.2002.00871.x

Rizk A, Curley J, Robertson J, Raber J (2004) Anxiety and cognition in histamine H3 receptor−/− mice. Eur J Neurosci 19:1992–1996. https://doi.org/10.1111/j.1460-9568.2004.03251.x

doi: 10.1111/j.1460-9568.2004.03251.x pubmed: 15078574

Sanna MD, Stark H, Lucarini L et al (2015) Histamine H 4 receptor activation alleviates neuropathic pain through differential regulation of ERK, JNK, and P38 MAPK phosphorylation. Pain 156:2492–2504. https://doi.org/10.1097/j.pain.0000000000000319

doi: 10.1097/j.pain.0000000000000319 pubmed: 26270581

Sanna MD, Ghelardini C, Thurmond RL et al (2017) Behavioural phenotype of histamine H4 receptor knockout mice: focus on central neuronal functions. Neuropharmacology 114:48–57. https://doi.org/10.1016/j.neuropharm.2016.11.023

doi: 10.1016/j.neuropharm.2016.11.023 pubmed: 27899280

Sanna MD, Borgonetti V, Masini E, Galeotti N (2020) Histamine H4 receptor stimulation in the locus coeruleus attenuates neuropathic pain by promoting the coeruleospinal noradrenergic inhibitory pathway. Eur J Pharmacol 868. https://doi.org/10.1016/j.ejphar.2019.172859

Savola JM, Hill M, Engstrom M et al (2003) Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Mov Disord 18:872–883. https://doi.org/10.1002/mds.10464

doi: 10.1002/mds.10464 pubmed: 12889076

Schneider EH, Seifert R (2016) The histamine H4-receptor and the central and peripheral nervous system: a critical analysis of the literature. Neuropharmacology 106:116–128

doi: 10.1016/j.neuropharm.2015.05.004

Searles Nielsen S, Gross A, Camacho-Soto A et al (2018) β2-adrenoreceptor medications and risk of Parkinson disease. Ann Neurol 84:683–693. https://doi.org/10.1002/ana.25341

doi: 10.1002/ana.25341 pubmed: 30225948

Shan L, Bossers K, Luchetti S et al (2012a) Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson’s patients: a postmortem study. Neurobiol Aging 33:1488.e1–1488.e13. https://doi.org/10.1016/j.neurobiolaging.2011.10.016

doi: 10.1016/j.neurobiolaging.2011.10.016

Shan L, Liu CQ, Balesar R et al (2012b) Neuronal histamine production remains unaltered in Parkinson’s disease despite the accumulation of Lewy bodies and Lewy neurites in the tuberomamillary nucleus. Neurobiol Aging 33:1343–1344. https://doi.org/10.1016/j.neurobiolaging.2011.01.004

doi: 10.1016/j.neurobiolaging.2011.01.004 pubmed: 21371786

Shan L, Swaab DF, Bao AM (2013) Neuronal histaminergic system in aging and age-related neurodegenerative disorders. Exp Gerontol 48:603–607. https://doi.org/10.1016/j.exger.2012.08.002

doi: 10.1016/j.exger.2012.08.002 pubmed: 22910064

Shan L, Bao AM, Swaab DF (2015a) The human histaminergic system in neuropsychiatric disorders. Trends Neurosci 38:167–177. https://doi.org/10.1016/j.tins.2014.12.008

doi: 10.1016/j.tins.2014.12.008 pubmed: 25575625

Shan L, Dauvilliers Y, Siegel JM (2015b) Interactions of the histamine and hypocretin systems in CNS disorders. Nat Rev Neurol 11:401–413. https://doi.org/10.1038/nrneurol.2015.99

doi: 10.1038/nrneurol.2015.99 pubmed: 26100750 pmcid: 8744538

Spencer KR, Foster ZW, Rauf NA et al (2020) Neuropathological profile of long-duration amyotrophic lateral sclerosis in military veterans. Brain Pathol 30:1028–1040. https://doi.org/10.1111/bpa.12876

doi: 10.1111/bpa.12876 pubmed: 32633852 pmcid: 8018169

Strakhova MI, Nikkel AL, Manelli AM et al (2009) Localization of histamine H4 receptors in the central nervous system of human and rat. Brain Res 1250:41–48. https://doi.org/10.1016/j.brainres.2008.11.018S0006-8993(08)02729-7

doi: 10.1016/j.brainres.2008.11.018S0006-8993(08)02729-7 pubmed: 19046950

Sulzer D (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends Neurosci 30:244–250

doi: 10.1016/j.tins.2007.03.009

Szakacs Z, Dauvilliers Y, Mikhaylov V et al (2017) Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:200–207. https://doi.org/10.1016/S1474-4422(16)30333-7

doi: 10.1016/S1474-4422(16)30333-7 pubmed: 28129985

Takahashi K, Suwa H, Ishikawa T, Kotani H (2002) Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J Clin Invest 110:1791–1799. https://doi.org/10.1172/JCI15784

doi: 10.1172/JCI15784 pubmed: 12488429 pmcid: 151650

Thannickal TC, Moore RY, Nienhuis R et al (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469–474

doi: 10.1016/S0896-6273(00)00058-1

Thurmond RL, Gelfand EW, Dunford PJ (2008) The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 7:41–53. https://doi.org/10.1038/nrd2465nrd2465

doi: 10.1038/nrd2465nrd2465 pubmed: 18172439

Thurmond RL, Venable J, Savall B et al (2017) Clinical development of histamine H4 receptor antagonists. In: Handbook of experimental pharmacology. Springer LLC, New York, pp 1–20

Tiligada E, Ennis M (2020) Histamine pharmacology: from Sir Henry Dale to the 21st century. Br J Pharmacol 177:469–489. https://doi.org/10.1111/bph.14524

doi: 10.1111/bph.14524 pubmed: 30341770

Uguen M, Perrin D, Belliard S et al (2013) Preclinical evaluation of the abuse potential of Pitolisant, a histamine H3 receptor inverse agonist/antagonist compared with Modafinil. Br J Pharmacol 169:632–644. https://doi.org/10.1111/bph.12149

doi: 10.1111/bph.12149 pubmed: 23472741 pmcid: 3682710

Volonté C, Apolloni S, Sabatelli M (2019) Histamine beyond its effects on allergy: potential therapeutic benefits for the treatment of amyotrophic lateral sclerosis (ALS). Pharmacol Ther 202:120–131

doi: 10.1016/j.pharmthera.2019.06.006

Watanabe T, Taguchi Y, Hayashi H et al (1983) Evidence for the presence of a histaminergic neuron system in the rat brain: an immunohistochemical analysis. Neurosci Lett 39:249–254

doi: 10.1016/0304-3940(83)90308-7

Yoshikawa T, Nakamura T, Yanai K (2020) Histaminergic neurons in the tuberomammillary nucleus as a control centre for wakefulness. Br J Pharmacol

Yu X, Ye Z, Houston CM et al (2015) Wakefulness is governed by GABA and histamine Cotransmission. Neuron 87:164–178. https://doi.org/10.1016/j.neuron.2015.06.003

doi: 10.1016/j.neuron.2015.06.003 pubmed: 26094607 pmcid: 4509551

Zhang W, Zhang X, Zhang Y et al (2020) Histamine induces microglia activation and the release of proinflammatory mediators in rat brain via H1R or H4R. J Neuroimmune Pharmacol 15:280–291. https://doi.org/10.1007/s11481-019-09887-6

doi: 10.1007/s11481-019-09887-6 pubmed: 31863333

Zhou P, Homberg JR, Fang Q et al (2019) Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model. Brain Behav Immun 76:61–73. https://doi.org/10.1016/j.bbi.2018.11.006

doi: 10.1016/j.bbi.2018.11.006 pubmed: 30408497

Zhu Y, Michalovich D, Wu H et al (2001) Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol 59:434–441

doi: 10.1124/mol.59.3.434

Histamine-4 Receptor: Emerging Target for the Treatment of Neurological Diseases.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Ling Shan (L)

Gerard J M Martens (GJM)

Dick F Swaab (DF)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH